Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis

Otolaryngology - Head and Neck Surgery

Volumn 127, Issue 6 SUPPL., 2002, Pages

  Dandekar, Prachi K ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CECLOR CD; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFDITOREN PIVOXIL; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFTIBUTEN; CEFUROXIME AXETIL; CEPHALOSPORIN; LORACARBEF; PENICILLIN G; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; HUMAN; INTERSTITIAL FLUID; MINIMUM INHIBITORY CONCENTRATION; RHINOSINUSITIS; TREATMENT OUTCOME; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; REVIEW; RHINITIS; SINUSITIS; TIME;

ADMINISTRATION, ORAL; CEPHALOSPORINS; HUMANS; PHARMACOKINETICS; RHINITIS; SINUSITIS; TIME FACTORS;

EID: 0036981532     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhn.2002.130110     Document Type: Article

References (23)

1. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000;123(1 pt 2):S1-S32.
2. Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-2, 1998
4. Nicolau DP. Using pharmacodynamic/pharmacokinetic surrogate markers in clinical practice: optimizing antibiotic therapy in respiratory tract infections. Am J Health Syst Pharm 1999;56(Suppl 3):S16-S20.
5. Garrison MW, Malone CL, Eiland JE. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996;40:1545-7.
6. Eagle H, Fleischman R, Musselman AD. Effect of schedule of administration on therapeutic efficacy of penicillin: importance of aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950;9:280-99.
7. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
8. Onyeji CO, Nicolau DP, Nightingale CH, et al. Optimal duration of time above the minimum inhibitory concentrations of ceftibuten and cefaclor in an experimental abdominal infections. Antimicrob Agents Chemother 1994;38:1112-7.
9. Nicolau DP, Onyeji CO, Zhong M, et al. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 2000;44:1291-5.
10. Knudsen JD, Frimodt-Moller N, Espersen F. Experimental Streptococcus pneumoniae infection in mice for studying correlation in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother 1995; 39:1253-8.
11. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
12. Drusano GL, Goldstein FW. Relevance of the Alexander project: pharmacodynamic considerations. J Antimicrob Chemother 1996;(Suppl A):141-54.
13. Nicolau DP, Nightingale CH, Quintiliani R. Antibiotic kinetics and dynamics for the clinician. In: Cunha B, editor. Medical clinics of North America. Philadelphia: W.B. Saunders; 1995. p. 477-95.
14. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or gentamicin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
15. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
16. Brueggemann AB, Pfaller MA, Doern GV. Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae. J Clin Microbiol 2001;39:367-9.
17. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S81-S93.
18. Owens RC, Nightingale CH, Nicolau DP. Ceftibuten: an overview. Pharmacotherapy 1997;17:707-20.
19. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995;28:361-84.
20. Marchese A, Saverino D, Debbia EA, et al. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone, and in combination with other antibiotics, at supra- and sub-MIC levels. J Antimicrob Chemother 1995;35:53-66.
21. Kuti JL, Quintiliani R. Cefditoren pivoxil: a novel broadspectrum oral cephalosporin. Formulary 2001;36:265-75.
22. Wise R, Andrews JM, Thomber D. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin. J Antimicrob Chemother 1991;28:239-48.
23. Paek KS, Kim MY, Lee CS, Youn H. In vitro and in vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens. Antimicrob Agents Chemother 2000;44:3272-7.